Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Orteronel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Millennium Pharmaceuticals, Inc.